ILA Stock Overview
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Island Pharmaceuticals Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.056 |
52 Week High | AU$0.17 |
52 Week Low | AU$0.05 |
Beta | 0.32 |
1 Month Change | -6.67% |
3 Month Change | -35.63% |
1 Year Change | n/a |
3 Year Change | -85.45% |
5 Year Change | n/a |
Change since IPO | -89.91% |
Recent News & Updates
Recent updates
Shareholder Returns
ILA | AU Pharmaceuticals | AU Market | |
---|---|---|---|
7D | 5.7% | 5.2% | -1.3% |
1Y | n/a | 39.1% | 6.0% |
Return vs Industry: Insufficient data to determine how ILA performed against the Australian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ILA performed against the Australian Market.
Price Volatility
ILA volatility | |
---|---|
ILA Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 10.3% |
Market Average Movement | 9.0% |
10% most volatile stocks in AU Market | 17.7% |
10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: ILA's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ILA's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | n/a | David Foster | www.islandpharmaceuticals.com |
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing various molecules that could be searched for drug re-purposing and pipeline development.
Island Pharmaceuticals Limited Fundamentals Summary
ILA fundamental statistics | |
---|---|
Market cap | AU$6.37m |
Earnings (TTM) | -AU$2.37m |
Revenue (TTM) | AU$960.12k |
6.6x
P/S Ratio-2.7x
P/E RatioIs ILA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ILA income statement (TTM) | |
---|---|
Revenue | AU$960.12k |
Cost of Revenue | AU$610.56k |
Gross Profit | AU$349.56k |
Other Expenses | AU$2.72m |
Earnings | -AU$2.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.021 |
Gross Margin | 36.41% |
Net Profit Margin | -247.34% |
Debt/Equity Ratio | 79.6% |
How did ILA perform over the long term?
See historical performance and comparison